Clinical trials: Patient Derived Organoid
Small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer
This study plans to enroll 20 patients with recurrent small cell lung cancer. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans.
- Trial name
- NCT06406660
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence.
- Trial name
- NCT06406608
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Glioblastoma, Organoid
Drug Response Testing and Repurposing Using Glioblastoma Organoid
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including…
- Trial name
- NCT06782984
- Testing
- Organoid-based drug sensitivity test
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Chungnam National University Hospital
Ovarian Cancer
Patients Derived Organoids in Ovarian Cancer
Among cancer models, patients derived organoids (PDOs) best reproduce tumor's tissue architecture, intratumor heterogeneity and are able to mimic in vivo patients' drugs response.
- Trial name
- PICTURE (NCT06085404)
- Testing
- Blood sample
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Invasive Breast Cancer
Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy
The aim of this study is to establish patient-derived organoid (PDO) and tumor tissue cultures from breast cancer patients, in order to create personalized, accurate, and reliable preclinical models capable of providing…
- Trial name
- PDO-Neo01 (NCT07260188)
- Testing
- Blood and tumor tissue collection
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome
In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.
- Trial name
- NCT05400239
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Ovarian Cancer
Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).
The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors.
- Trial name
- PANDORA (NCT06229522)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Lung Cancer, Non-Small Cell
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to…
- Trial name
- NCT06405230
- Testing
- Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin)
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Organoid
Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer
This is a single-center, single-arm, open and exploratory clinical study. The purpose of this study was to evaluate the consistency and accuracy of the organogenic (PDO) model for patients with lung cancer, to predict the…
- Trial name
- NCT05669586
- Testing
- Antitumor therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Breast Cancer
Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer
Based on proof-of-concept study, the investigators hypothesise that the QPOP prediction model can be further extended into use in solid tumors.
- Trial name
- QUEST (NCT05177432)
- Testing
- QPOP
- Where
- Singapore
- Volunteers
- 26 people
- Sponsor
- National University Hospital, Singapore
Hepatocellular Carcinoma, Colorectal Cancer
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
Precision oncology aims to improve clinical outcome of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumors.
- Trial name
- PDO (NCT06077591)
- Testing
- Patient-Derived Tumor Organoids
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Breast Cancer
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO).
- Trial name
- AVATAR (NCT06459791)
- Testing
- Biopsy
- Where
- 3 sites in France
- Volunteers
- 110 people
- Sponsor
- Institut Curie
Primary Sclerosing Cholangitis, PSC
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
- Conditions
- Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
- Trial name
- NCT04753996
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Salivary Gland Cancers, Patient Derived Organoid
PDO Based Drug Sensitive Test in R/M SGC
To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M SGC patients, using a prospective and multicenter observational study to…
- Conditions
- Salivary Gland Cancers, Patient Derived Organoid, Drug Sensitive Test in Vitro
- Trial name
- NCT06686979
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Huashan Hospital
Peutz-Jeghers Syndrome
Chinese Multicenter Registry for Peutz-Jeghers Syndrome
This prospective, observational patient registry will enroll approximately 1,000 individuals with a clinical or molecular diagnosis of Peutz-Jeghers syndrome (PJS) at participating hospitals in China.
- Trial name
- NCT07889596
- Where
- 9 sites in China
- Volunteers
- 1,000 people
- Sponsor
- First People's Hospital of Hangzhou
Pancreatic Ductal Adenocarcinoma (PDAC)
Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer
1. Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide, with a 5-year survival rate below 10%.
- Trial name
- NCT07683845
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Beijing Daxiang Biotech Co., Ltd
Organoids
Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors
Recent studies that ex vivo drug responses on PDO models across different solid tumours can predict treatment responses to chemotherapeutic agents.
- Trial name
- NCT05378048
- Testing
- PDO-guided treatment, standard of care
- Where
- Hong Kong
- Sponsor
- Chinese University of Hong Kong
Ovarian Cancer
The Culture of Ovarian Cancer Organoids and Drug Screening
The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory…
- Trial name
- NCT04768270
- Testing
- no intervention
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Lung Cancer, Lung Adenocarcinoma
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Lung cancer is a major public health problem and remains the leading cause of cancer mortality worldwide. Moreover, in France, it is the 3rd most common cancer in terms of incidence.
- Conditions
- Lung Cancer, Lung Adenocarcinoma, EGFR Activating Mutation, KRAS Mutation-Related Tumors
- Trial name
- OS-TUMOVASC (NCT05136014)
- Testing
- Collection of surgical waste
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Central Hospital, Nancy, France
Neuroendocrine Neoplasm
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
The aim of this study is to use single-cell sequencing technology to explore neuroendocrine neoplasm (NEN) molecular biological characteristics, tumor heterogeneity and cell subtypes. Besides.
- Trial name
- NCT04927611
- Testing
- Biopsy, open or laparoscopic surgery
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University